Predica Diagnostics B.V. is active in the field of diagnostics, prognostics and prediction of treatment response in oncology. Our platform technology is based on targeted RNA sequencing, making use of proprietary probes, next generation sequencing and unique algorithms. Predica Diagnostics first product, the CervicaDX test, allows non-invasive detection of cervical abnormalities in women who are at risk of developing cervical cancer. After successful implementation of the CervicaDx test, Predica Diagnostics intends to expand its portfolio with diagnostic tests for other types of cancer. These tests generate a histology-independent molecular diagnosis, predict a prognosis and produce a list of potentially successful precision medicines, thus aiding in development of personalized treatment plans for cancer patients.